Eupraxia Pharmaceuticals Inc.
EPRX
$5.96
-$0.03-0.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.47M | -38.58M | -29.37M | -28.96M | -26.22M |
| Total Depreciation and Amortization | 281.30K | 237.70K | 219.40K | 194.20K | 180.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.69M | 10.50M | 4.27M | 4.63M | 3.90M |
| Change in Net Operating Assets | 2.80M | -713.70K | 86.60K | -6.35M | -7.72M |
| Cash from Operations | -32.70M | -28.55M | -24.80M | -30.48M | -29.86M |
| Capital Expenditure | -746.90K | -588.90K | -439.90K | -421.80K | -266.40K |
| Sale of Property, Plant, and Equipment | -- | -- | 600.00 | 600.00 | 29.10K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.72M | -- | -- | -- | -- |
| Cash from Investing | -80.47M | -588.90K | -439.40K | -421.30K | -237.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | -4.60M | -9.12M |
| Issuance of Common Stock | 144.21M | 76.06M | 106.30M | 32.40M | 32.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 144.21M | 76.06M | 106.30M | 27.80M | 23.04M |
| Foreign Exchange rate Adjustments | 1.10K | 544.80K | -764.60K | -448.40K | -1.40M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.05M | 47.46M | 80.30M | -3.55M | -8.45M |